CTIS2022-501648-14-00招募中1 期
ong-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies - M-2022-393
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Patient underwent treatment with a Miltenyi CAR T cell therapy at least 12 months prior to enrollment in long-term follow-up, Patient has provided informed consent prior to enrollment
排除标准
- •No exclusion criteria are defined for this long-term follow-up trial
研究者
相似试验
进行中（未招募）
1 期
A long-term follow-up study for patients treated with Galapagos CAR T cell therapiesRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-510173-34-00Galapagos300
招募中
1 期
A phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma patientsGlioblastomaJPRN-jRCTs031200326arita Yoshitaka22
进行中（未招募）
1 期
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsEUCTR2019-003518-15-ROCelltrion, Inc.216
进行中（未招募）
1 期
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 4.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsEUCTR2019-003518-15-PLCelltrion, Inc.350
招募中
Unknown
ong-term follow-up study after 'Treatment of lumbar canal stenosis with a combination of ultra-purified, allogenic, bone marrow-derived, mesenchymal stem cells (REC) and in situ-forming gel: a multicentre, prospective, double blind, randomised, controlled trial'JPRN-jRCT1010230005Hideki Sudo45